Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About?
Celldex Therapeutics, Inc. (CLDX) is drawing market attention after its barzolvolimab studies in chronic spontaneous urticaria met primary and key secondary endpoints. This development highlights the company's operating priorities and its position within the Healthcare Stocks sector. Investors are now focused on consistent execution and how these positive clinical results translate into sustained operational success and customer response.
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64
H.C. Wainwright has reiterated its Buy rating for Celldex Therapeutics (CLDX.US), maintaining a target price of $64. This indicates continued confidence from the analyst firm in the company's prospects.
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
Celldex Therapeutics (CLDX) recently announced positive Phase 3 trial results for its lead asset, barzolvolimab, in chronic spontaneous urticaria, demonstrating best-in-disease efficacy and high rates of complete response. While the company has a strong cash balance and a broad pipeline, it faces a heavy burn rate with widening net losses and a BLA submission not expected until 2027. The market is divided on CLDX, reflecting both the clinical promise of barzolvolimab and the financial challenges and mixed results from other programs.
Celldex Therapeutics upgraded to Buy after positive Phase 3 trial results for skin drug barzolvolimab.
Celldex Therapeutics received a "Buy" rating upgrade from H.C. Wainwright, with a price target increase to $64 from $42, following successful Phase 3 trials for its skin drug barzolvolimab. The drug demonstrated rapid and lasting benefits for patients with a chronic skin condition, and Celldex plans to seek FDA approval in 2027. This development highlights significant progress for the company and provides context for the positive performance of health-sector stocks.
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Therapeutics announced positive top-line results from its Phase III EMBARQ-CSU trials for barzolvolimab, a treatment for chronic spontaneous urticaria (CSU). Both dosing regimens met primary and key secondary endpoints, showing significant and durable improvements in UAS7 scores and high rates of complete response, including in omalizumab-refractory patients and those with angioedema. The safety profile was consistent with previous studies, and Celldex plans to submit a Biologics License Application (BLA) in 2027.
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics announced positive topline results from its Phase 3 EMBARQ-CSU clinical trials for barzolvolimab, a treatment for chronic spontaneous urticaria (CSU). Both trials met primary and key secondary endpoints, showing significant improvement in patients, including those refractory to existing therapies. The company plans to submit a Biologics License Application (BLA) to the FDA in 2027 based on these favorable results and a consistent safety profile.
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
This article highlights four biotech companies—Kodiak Sciences (KOD), Celldex Therapeutics (CLDX), Rapport Therapeutics (RAPP), and Vaxcyte (PCVX)—that have significant clinical readouts anticipated this fall. These readouts are critical catalysts for biotech stocks, as positive or negative data can substantially impact investor expectations and stock valuations. The companies are advancing drug candidates in ophthalmology, immunology, neuroscience, and vaccines, with potential for major valuation shifts based on study outcomes.
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
Celldex Therapeutics announced that its drug Barzolvolimab met the primary and all key secondary endpoints in two Phase 3 trials for chronic spontaneous urticaria. This positive outcome follows a recent setback where the company discontinued a Phase 2 study for the same drug in Prurigo Nodularis due to missing its primary endpoint. Despite the mixed results, analysts maintain an "Overweight" rating on Celldex, with an average target price significantly above the current stock price.
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
Celldex Therapeutics saw its shares rise 8% after announcing positive topline results from two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) for its drug barzolvolimab in patients with chronic spontaneous urticaria (CSU). Both trials met primary and key secondary endpoints, showing significant improvements in disease activity and complete response rates compared to placebo, even in difficult-to-treat patients. Celldex plans to submit a Biologics License Application (BLA) for barzolvolimab to the FDA in 2027.
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
Celldex Therapeutics announced that its drug barzolvolimab met primary endpoints in two Phase 3 trials for chronic spontaneous urticaria. The article, however, is a premium content piece from MT Newswires, requiring a subscription to Yahoo Finance Gold or Silver to access the full details.
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Celldex (NASDAQ:CLDX) reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for barzolvolimab in patients with chronic spontaneous urticaria (CSU), meeting primary and all key secondary endpoints. The studies demonstrated rapid, profound, and sustained efficacy, with a favorable safety profile. Celldex plans to submit a Biologics License Application (BLA) in 2027, positioning barzolvolimab as a potential transformational therapy for CSU, including those refractory to existing treatments.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
Purcell & Lefkowitz LLP has launched a shareholder investigation into Celldex Therapeutics, Inc. (NASDAQ: CLDX) to determine if the company's directors breached their fiduciary duties through recent corporate actions. Shareholders of Celldex Therapeutics are encouraged to contact the firm for more information regarding their rights and options. Purcell & Lefkowitz LLP specializes in representing shareholders affected by securities fraud and corporate misconduct.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of "Moderate Buy" by Brokerages
Celldex Therapeutics (NASDAQ:CLDX) has received a consensus "Moderate Buy" rating from thirteen research firms, with an average 12-month price target of $56.42. The company recently reported quarterly EPS of -$0.94, surpassing estimates, though revenue fell short. Several institutional investors have significantly increased their holdings in CLDX, and analysts expect a full-year loss of approximately $4.17 per share.
Celldex to Present at Upcoming Investor Conference
Celldex Therapeutics, Inc. announced that its management will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026, at 8:00 AM ET. A webcast of the presentation will be available on the "Events and Presentations" page of the "Investors" section of the Celldex Website, with replays available for 90 days. Celldex focuses on pioneering antibody-based treatments for allergic, inflammatory, and autoimmune disorders.
Discipline and Rules-Based Execution in CLDX Response
The article analyzes Celldex Therapeutics Inc. (NASDAQ: CLDX), noting weak near and mid-term sentiment despite a strong long-term outlook. It highlights a significant 42.0:1 risk-reward setup targeting a 12.4% gain against 0.3% risk, and provides three AI-generated trading strategies for different risk profiles. The analysis emphasizes rules-based execution and sophisticated risk management.
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX
Celldex Therapeutics, Inc. (NASDAQ:CLDX) generated $1.54 million USD in revenue last year, primarily from its "Novel Therapeutics for Human Health Care" segment. This figure represents a decrease from the $7.02 million USD reported the previous year. The United States was the largest contributor to the company's revenue, mirroring the overall revenue figures.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $56.08, exceeding its current share price of $41.70. While recent analyst actions were mixed, including Guggenheim raising its target to $100 and Cantor Fitzgerald cutting its target to $61, the overall sentiment remains positive. The company reported a quarterly loss of $0.94 per share, beating expectations, but revenue of $0.02 million missed estimates significantly.
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 70.8% in the first quarter, now owning 708,647 shares valued at $22.5 million. This comes as Celldex, a clinical-stage biopharmaceutical company, reported a smaller-than-expected quarterly loss of $0.94 per share. Analysts maintain a "Moderate Buy" consensus rating for CLDX, with an average price target of $55.46.
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake
Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a SCHEDULE 13G/A, indicates that no single entity among the reporting persons holds sole voting or dispositive power over these shares.
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G
T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 shares. Despite the disclosure, T. Rowe Price Associates explicitly states that this report should not be interpreted as an admission of beneficial ownership.
Celldex Therapeutics (CLDX) Reported Wider Losses, Is It Still Undervalued?
Celldex Therapeutics (CLDX) recently reported wider losses and lower revenue for Q2 and H1 2026, yet its stock has seen significant recent gains. While the company trades at a 4.9x Price-to-Book multiple, suggesting it's overvalued compared to peers, a Discounted Cash Flow (DCF) model indicates it's trading 61.1% below its estimated intrinsic value of $113.93 per share. Investors are left to weigh the company's widening losses and P/B valuation against its strong recent stock performance and potential future cash flow value.
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX
Sei Investments Co. recently acquired a new stake of 38,152 shares in Celldex Therapeutics, Inc., valued at approximately $1.21 million. This comes as several other hedge funds have also adjusted their positions in the biopharmaceutical company. Celldex Therapeutics reported better-than-expected quarterly earnings and has received new price targets from analysts, with a consensus of "Moderate Buy."
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress
Celldex Therapeutics (CLDX) reported wider Q2 and first-half losses totaling US$73.5 million and US$152.19 million, respectively, yet its stock rose by 10.7%. This increase is attributed to positive Phase 1 data for bispecific antibody CDX-622 and continued Phase 3 progress for barzolvolimab, despite minimal revenue. The company's investment narrative hinges on the success of its barzolvolimab Phase 3 program and broader allergy and immunology pipeline justifying its premium valuation despite growing losses and funding needs.
Celldex Therapeutics (NasdaqCM:CLDX) Stock Forecast & Analyst Predictions
Celldex Therapeutics (CLDX) is forecast to grow earnings by 41.7% and revenue by 71.5% per annum. The company recently completed enrollment for its Phase 3 trials of barzolvolimab in chronic spontaneous urticaria (CSU) and initiated a Phase 3 trial for cold urticaria (ColdU) and symptomatic dermographism (SD), with topline data for CSU expected in Q4 2026 and a BLA filing targeted for 2027. Despite strong clinical progress with its mast cell-targeted therapies, Celldex remains unprofitable and faces risks associated with revenue generation, shareholder dilution, and potential delays in trial readouts.
Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX
Quantinno Capital Management LP significantly increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 178.7% in the first quarter, purchasing an additional 42,158 shares to own a total of 65,744 shares valued at $2.09 million. This move comes as institutional investors continue to adjust their positions in the biopharmaceutical company, which has seen generally positive analyst sentiment, with an average price target of $55.46 and a "Moderate Buy" consensus rating. Celldex Therapeutics recently reported a quarterly loss that beat estimates but fell short on revenue, while its stock opened near its 52-week high.
Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX
Assenagon Asset Management S.A. significantly increased its stake in Celldex Therapeutics, purchasing an additional 642,171 shares, bringing its total to 788,696 shares valued at $29.35 million. This move comes as several other institutional investors also adjusted their positions in the biopharmaceutical company. Analysts maintain a "Moderate Buy" rating for Celldex, with updated price targets from Guggenheim ($100) and Wells Fargo ($72).
First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX
First Trust Advisors LP significantly increased its stake in Celldex Therapeutics, adding 78.7% more shares in the first quarter to reach a total holding of $2.17 million. Other institutional investors also raised or initiated positions. Despite missing revenue estimates, Celldex Therapeutics reported a narrower-than-expected quarterly loss, and analysts maintain a "Moderate Buy" rating with an average price target of $55.46.
Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside
The average 12-month price target for Celldex Therapeutics, Inc. (CLDX) stock has been raised from $57.07 to $58.07 by 15 analysts, with individual forecasts ranging from $38 to $100 per share. This new target suggests a potential upside of approximately 40% based on the August 6th closing price. The consensus analyst rating remains a "Buy," with 15 out of 16 analysts recommending a Buy and 1 recommending a Hold.
Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary
Celldex Therapeutics, Inc. reported its financial results for the quarter ended 2026, with revenue of $22K and a diluted loss per share of ($0.94), resulting in a net loss of ($73.5M) due to ongoing investments in trials and manufacturing. The company highlighted clinical milestones, including completed enrollment for Phase 3 CSU trials, initiation of Phase 3 for ColdU/SD, and advancements in its bispecific platform candidate CDX-622. R&D spending significantly increased, primarily driven by barzolvolimab-related activities and scaling of commercial manufacturing.
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
Celldex reported its second-quarter 2026 financial results, highlighting ongoing Phase 3 studies for barzolvolimab in chronic spontaneous urticaria with topline data expected in Q3/Q4 2026, and actively enrolling patients for cold urticaria and symptomatic dermographism studies. The company also announced positive Phase 1 results for its bispecific antibody CDX-622 and is advancing its development into additional indications while discontinuing the Phase 2 prurigo nodularis study due to not meeting efficacy endpoints. Celldex's cash position stands at $717.6 million, projected to fund operations through 2028 despite an increased net loss compared to the previous year.
Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million
Celldex reported a wider net loss of $
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M
Celldex Therapeutics, Inc. (CLDX) announced its Q2 revenue was $0.0M, as detailed in an earnings flash from MarketScreener. The company, a clinical-stage biotechnology firm, focuses on developing antibody-based therapeutics for inflammatory, allergic, autoimmune, and other diseases. Recent news also included adjustments to price targets by Morgan Stanley and the discontinuation of a Phase 2 study for Barzolvolimab in Prurigo Nodularis.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) reported a Q2 loss of $0.94 per share, which was better than the Zacks Consensus Estimate of a $1.04 loss, but missed revenue estimates significantly, posting only $0.02 million against an expectation of $0.73 million. Despite the revenue miss, the company's shares have risen over 51% year-to-date, outperforming the S&P 500, and currently hold a Zacks Rank #2 (Buy).
Dimensional Fund Advisors LP Has $33.60 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX
Dimensional Fund Advisors LP significantly increased its stake in Celldex Therapeutics, adding over 400,000 shares to hold 1.06 million shares valued at $33.6 million. Despite Celldex reporting a larger-than-expected quarterly loss and negligible revenue, analysts maintain a "Moderate Buy" rating with an average price target of $54.62. Several other institutional investors have also adjusted their positions in the biopharmaceutical company.
Celldex Therapeutics earnings up next as Phase III data looms By Investing.com
Celldex Therapeutics is set to report its second-quarter earnings, with investors focusing on the timing of topline data from its pivotal Phase III EMBARQ-CSU studies, expected in September to October. Analysts project a loss of $1.06 per share on revenue of $803,000, and Wall Street maintains a strong-buy consensus despite a recent Phase 2 trial failure. The earnings call will also address resource allocation after the discontinuation of the prurigo nodularis study and the company's cash position given its substantial burn rate.
Celldex Therapeutics stock hits 52-week high at $40.30
Celldex Therapeutics (CLDX) stock hit a new 52-week high of $40.30, with shares up 73% in the past six months and 86.85% over the past year, reflecting strong investor confidence. Despite this surge, InvestingPro data suggests the stock is currently overvalued. The company faces mixed news, including the discontinuation of a Phase II study for barzolvolimab in prurigo nodularis, leading to a lowered price target from Canaccord, but also positive outlooks for its chronic spontaneous urticaria trial from Guggenheim and UBS.
Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com
Celldex Therapeutics stock reached a 52-week high of $40.30, showcasing significant investor confidence with an 86.85% increase over the past year. Despite this surge and a market capitalization of $3.16 billion, InvestingPro data suggests the stock is currently overvalued. The company faces mixed news, including the discontinuation of a Phase II study for prurigo nodularis, but positive outlooks for a chronic spontaneous urticaria trial and reiterated Buy ratings from some analysts.
Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus
Celldex Therapeutics (CLDX) is under scrutiny following its Phase 2 clinical trial results for prurigo nodularis. The stock has seen significant momentum with strong share price returns over the last year, leading to questions about its valuation. While it trades at a discount compared to direct peers based on price-to-book ratio, it appears expensive against the broader US biotech industry, prompting investors to assess whether the market is overly cautious or conservative about its potential.
Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Celldex Therapeutics Inc (CLDX), noting its current valuation score of 6.88, which ranks 244 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.92, indicating a position between its recent high and low P/E values. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial analysis of Celldex Therapeutics Inc (CLDX), highlighting its current financial score of 5.70, which ranks 328 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency, marked by a significant year-over-year decrease in quarterly revenue and net profit. The analysis breaks down various financial dimensions including cash and cash equivalents, total assets, total liabilities, and free cash flow.
CLDX|Celldex Therapeutics Inc|Price:35.660|Chg%:+0.380
This article provides a comprehensive stock analysis of Celldex Therapeutics Inc (CLDX) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company's fundamentals are considered healthy with significant growth potential, and it is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have rated CLDX as a Buy, with expectations for the stock price to trend upward in the medium term.
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Celldex Therapeutics Inc (CLDX), listing major shareholders such as Wellington Management Company, LLP and BlackRock Institutional Trust Company, N.A., along with their respective holdings and proportions. It also breaks down shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities. Additionally, the article identifies related ETFs that hold CLDX stock.
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Celldex Therapeutics Inc (CLDX) has an earnings forecast score of 8.50, ranking 106th in the Biotechnology & Medical Research industry, with an average price target of $53.00. Analysts largely recommend a "Buy" for CLDX, with 16 analysts providing ratings. The company's expected revenue for the next quarter is $954.44K, and EPS for the next quarter is projected at USD -1.06.
Celldex Therapeutics, Inc. Revenue Breakdown – DUS:TCE2
Celldex Therapeutics, Inc. (DUS:TCE2) generated €1.32 million in revenue last year, primarily from its "Novel Therapeutics for Human Health Care" segment, a significant decrease from €6.78 million in the previous year. The United States was the company's largest regional contributor, matching the segment's revenue.
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run
Celldex Therapeutics (CLDX) stock has seen a significant 59.5% return over the past year, leading to a valuation that appears expensive when considering market multiples and P/B ratio. The company's P/B ratio of 6.1x is higher than the broader biotech industry average, indicating a premium valuation despite it being a clinical-stage biotech without current free cash flow. Investors need to weigh the potential of its clinical pipeline against the current high expectations embedded in its stock price and decide if the premium is justified by future progress and funding.
CELLDEX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $70 FROM $78
Leerink Partners has decreased its target price for Celldex Therapeutics Inc. from $78 to $70. This change was reported by Reuters two days prior to the crawl date, indicating a potential re-evaluation of the company's financial outlook by the analyst firm.
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
This article provides an update on several biopharma companies. Summit Therapeutics has released new data for its cancer immunotherapy ivonescimab, which shows improved survival rates in lung cancer patients, addressing investor skepticism. Celldex Therapeutics' autoimmune drug barzolvolimab failed a mid-stage trial for prurigo nodularis but is still anticipated to show positive results in a late-stage study for chronic spontaneous urticaria. Other updates include Gilead and Merck's new once-weekly HIV tablet data, Lupin spinning off two cancer drug prospects into a new startup, and Jupiter Neuroscience acquiring partial rights to an experimental psychedelic from PharmAla Biotech.
Stifel Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $68
Stifel has maintained its Buy rating on Celldex Therapeutics (CLDX.US) and reiterated a target price of $68. This indicates continued confidence from Stifel in the company's performance and future prospects.
Celldex Stands By Barzolvolimab in CSU After Prurigo Nodularis Miss
Celldex maintains confidence in its drug barzolvolimab for Chronic Spontaneous Urticaria (CSU) despite a recent trial failure in Prurigo Nodularis. The company's stance follows a previous study miss for the drug in August 2025. This article highlights Celldex's continued commitment to barzolvolimab for CSU.
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Celldex Therapeutics has discontinued its Phase 2 clinical trial for barzolvolimab in prur
